Skip to main content
SpringerLink
Log in

To avoid muscle-related adverse events, choose statins carefully in patients receiving antiviral protease inhibitors

  • DRUG REACTIONS AND INTERACTIONS
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The appropriate statin to treat co-morbid dyslipidaemia requires careful selection in patient with hepatitis C virus (HCV) infection receiving HCV protease inhibitors (e.g. telaprevir and boceprevir), and those with HIV-1 infection receiving ritonavir- or cobicistat-boosted HIV protease inhibitors. HCV and boosted-HIV protease inhibitors can increase the plasma concentrations of certain statins, thereby increasing the risk of the potential for statin-related myopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000;20(9):1066–7.

    Article  CAS  PubMed  Google Scholar 

  2. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61(2):238–45.

    Article  CAS  PubMed  Google Scholar 

  3. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–52.

    CAS  PubMed  Google Scholar 

  4. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug–drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31.

    Article  CAS  PubMed  Google Scholar 

  5. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441–57.

    Article  CAS  PubMed  Google Scholar 

  6. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343–70.

    Article  CAS  PubMed  Google Scholar 

  7. Ferenci P, Reddy KR. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection. Antivir Ther. 2011;16(8):1187–201.

    Article  CAS  PubMed  Google Scholar 

  8. Chopra A, Klein PL, Drinnan T, et al. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013;33(Suppl 1):30–4.

    Article  CAS  PubMed  Google Scholar 

  9. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387–402.

    Article  CAS  PubMed  Google Scholar 

  10. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses. 2012;28(10):1184–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–35.

    Article  PubMed  Google Scholar 

  12. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11(6):933–46.

    Article  CAS  PubMed  Google Scholar 

  13. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63(1):157–81.

    Article  CAS  PubMed  Google Scholar 

  14. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5(7):703–29.

    Article  CAS  PubMed  Google Scholar 

  15. Koenen A, Kroemer HK, Grube M, et al. Current understanding of hepatic and intestinal OATP-mediated drug–drug interactions. Expert Rev Clin Pharmacol. 2011;4(6):729–42.

    Article  CAS  PubMed  Google Scholar 

  16. Tamraz B, Fukushima H, Wolfe AR, et al. OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet Genomics. 2013;23(7):355–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 1999;39(1–3):211–38.

    Article  CAS  PubMed  Google Scholar 

  18. Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. 2007;76(3):203–21.

    Article  CAS  PubMed  Google Scholar 

  19. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005;78(6):605–18.

    Article  CAS  PubMed  Google Scholar 

  20. Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179–85.

    CAS  PubMed  Google Scholar 

  21. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2009;87(3):322–9.

    Article  PubMed  Google Scholar 

  22. Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014;74(2):195–205.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from Clinical Pharmacokinetics 2013;52(10):815–31 [4]. The preparation of this article was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. To avoid muscle-related adverse events, choose statins carefully in patients receiving antiviral protease inhibitors. Drugs Ther Perspect 30, 264–267 (2014). https://doi.org/10.1007/s40267-014-0122-8

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-014-0122-8

    Keywords

    Search

    Navigation